SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001176256-16-000495
Filing Date
2016-03-31
Accepted
2016-03-30 21:42:58
Documents
13
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 nymoxpharma20f151231.htm 20-F 1085671
2 COMMON STOCK PRIVATE PURCHASE AGREEMENT DATED NOVEMBER 1, 2013 exhibit4-w.htm EX-4.W 87107
3 6% SECURED CONVERTIBLE NOTE DATED DECEMBER 16, 2014 exhibit4-x.htm EX-4.X 54488
4 RESPONSE LETTER FROM KPMG IN THE CORPORATION'S 6-K DATED JULY 16, 2015 exhibit4-y.htm EX-4.Y 23578
5 SOX SECTION 302 CEO CERTIFICATION exhibit12-a.htm EX-12.A 5593
6 SOX SECTION 302 CFO CERTIFICATION exhibit12-b.htm EX-12.B 5560
7 SOX SECTION 906 CEO CERTIFICATION exhibit13-a.htm EX-13.A 1641
8 SOX SECTION 906 CFO CERTIFICATION exhibit13-b.htm EX-13.B 1607
9 kpmg1.jpg GRAPHIC 12481
10 kpmg2.jpg GRAPHIC 6726
11 kpmg3.jpg GRAPHIC 2265
12 nymoxpharma20f151231_p2x2x1.jpg GRAPHIC 28904
13 nymoxpharma20f151231_p2x2x2.jpg GRAPHIC 22547
  Complete submission text file 0001176256-16-000495.txt   1367374
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 161541511
SIC: 2835 In Vitro & In Vivo Diagnostic Substances